Detection of SNCA and FBN1 methylation in the stool as a biomarker for colorectal cancer

Disease Markers

Volumn 2015, Issue , 2015, Pages

  Li, Wen Han ^a   Zhang, Hao ^a   Guo, Qi ^b   Wu, Xuan Di ^c   Xu, Zi Sen ^a   Dang, Cheng Xue ^a   Xia, Peng ^a   Song, Yong Chun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Xi'An TB and Thoracic Tumor Hospital   (China)

^c Reproductive Center Maternal and Child Health Hospital of Shaanxi Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FBN1 PROTEIN; SNCA PROTEIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; ALPHA SYNUCLEIN; FIBRILLIN; SNCA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; EARLY DIAGNOSIS; FECES ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; MALE; OCCULT BLOOD; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; CASE CONTROL STUDY; CHEMISTRY; COLORECTAL TUMOR; FECES; GENETICS; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; AGED; ALPHA-SYNUCLEIN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA METHYLATION; EARLY DETECTION OF CANCER; FECES; FEMALE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED;

EID: 84924559742     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2015/657570     Document Type: Article

References (58)

1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," CA: Cancer Journal for Clinicians, Vol. 61, no. 2, pp. 69-90, 2011.
2. R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2013," CA: A Cancer Journal for Clinicians, Vol. 63, no. 1, pp. 11-30, 2013.
3. J. J. Sung, J. Y. Lau, K. L. Goh, and W. K. Leung, "Increasing incidence of colorectal cancer in Asia: implications for screening," The Lancet Oncology, Vol. 6, no. 11, pp. 871-876, 2005.
4. E. Quintero, A. Castells, L. Bujanda et al., "Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening," The New England Journal of Medicine, Vol. 366, no. 8, pp. 697-706, 2012.
5. R. E. Schoen, P. F. Pinsky, J. L. Weissfeld et al., "Colorectal-cancer incidence and mortality with screening flexible sigmoi-doscopy," The New England Journal of Medicine, Vol. 366, no. 25, pp. 2345-2357, 2012.
6. S. B. Baylin, "Mechanisms underlying epigenetically mediated gene silencing in cancer," Seminars in Cancer Biology, Vol. 12, no. 5, pp. 331-337, 2002.
7. P. W. Laird, "The power and the promise of DNA methylation markers," Nature Reviews Cancer, Vol. 3, no. 4, pp. 253-266, 2003.
8. W. M. Grady, A. Rajput, J. D. Lutterbaugh, and S. D. Markowitz, "Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer," Cancer Research, Vol. 61, no. 3, pp. 900-902, 2001.
9. N. Shivapurkar and A. F. Gazdar, "DNA methylation based biomarkers in non-invasive cancer screening," Current Molecular Medicine, Vol. 10, no. 2, pp. 123-132, 2010.
10. N. J. Belshaw, G. O. Elliott, E. A. Williams et al., "Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer," Cancer Epidemiology Biomarkers and Prevention, Vol. 13, no. 9, pp. 1495-1501, 2004.
11. W.-D. Chen, Z. J. Han, J. Skoletsky et al., "Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene," Journal of the National Cancer Institute, Vol. 97, no. 15, pp. 1124-1132, 2005.
12. K. Lenhard, G. T. Bommer, S. Asutay et al., "Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer," Clinical Gastroenterology and Hepatology, Vol. 3, no. 2, pp. 142-149, 2005.
13. W. K. Leung, K.-F. To, E. P. S. Man et al., "Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study," Clinical Chemistry, Vol. 50, no. 11, pp. 2179-2182, 2004.
14. Z. Petko, M. Ghiassi, A. Shuber et al., "Aberrantly methylated CDKN2A, MGMT, and MLH1 incolonpolyps and in fecal DNA from patients with colorectal polyps," Clinical Cancer Research, Vol. 11, no. 3, pp. 1203-1209, 2005.
15. X.-D. Wu, Y.-C. Song, P.-L. Cao et al., "Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer," Medical Oncology, Vol. 31, no. 4, article 894, 2014.
16. H. Zhang, Y.-C. Song, and C.-X. Dang, "Detection of hyperme-thylated spastic paraplegia-20 in stool samples of patients with colorectal cancer," International Journal of Medical Sciences, Vol. 10, no. 3, pp. 230-234, 2013.
17. W. M. Grady and J. M. Carethers, "Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis," Gastroenterology, Vol. 135, no. 4, pp. 1079-1099, 2008.
18. J. G. Herman, J. R. Graff, S. Myöhänen, B. D. Nelkin, and S. B. Baylin, "Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands," Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, no. 18, pp. 9821-9826, 1996.
19. C. Lengauer, "Cancer. An unstable liaison," Science (New York, NY), Vol. 300, no. 5618, pp. 442-443, 2003.
20. S. B. Baylin and J. E. Ohm, "Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?" Nature Reviews Cancer, Vol. 6, no. 2, pp. 107-116, 2006.
21. P. A. Jones and S. B. Baylin, "The fundamental role of epigenetic events in cancer," Nature Reviews Genetics, Vol. 3, no. 6, pp. 415-428, 2002.
22. R. F. Schwabe and C. Jobin, "The microbiome and cancer," Nature Reviews Cancer, Vol. 13, no. 11, pp. 800-812, 2013.
23. G. E. Lind, S. A. Danielsen, T. Ahlquist et al., "Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas," Molecular Cancer, Vol. 10, article 85, 2011.
24. Q. Guo, Y. Song, H. Zhang, X. Wu, P. Xia, and C. Dang, "Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients," Medical Oncology, Vol. 30, no. 4, article 695, 2013.
25. J. E. Allison, I. S. Tekawa, L. J. Ransom, and A. L. Adrain, "A comparison of fecal occult-blood tests for colorectal-cancer screening," The New England Journal of Medicine, Vol. 334, no. 3, pp. 155-159, 1996.
26. G. Castiglione, M. Zappa, G. Grazzini et al., "Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer," British Journal of Cancer, Vol. 74, no. 1, pp. 141-144, 1996.
27. X. Wang, Y. Y. Kuang, and X. T. Hu, "Advances in epigenetic biomarker research in colorectal cancer," World Journal of Gastroenterology, Vol. 20, no. 15, pp. 4276-4287, 2014.
28. C. Ostwald, M. Linnebacher, V. Weirich, and F. Prall, "Chromo-somally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification," International Journal of Oncology, Vol. 35, no. 2, pp. 321-327, 2009.
29. L. J. W. Bosch, S. Mongera, J. S. T. S. Droste et al., "Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection," Cellular Oncology, Vol. 35, no. 4, pp. 309-315, 2012.
30. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," CA: Cancer Journal for Clinicians, Vol. 61, no. 2, pp. 69-90, 2011.
31. R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2013," CA: A Cancer Journal for Clinicians, Vol. 63, no. 1, pp. 11-30, 2013.
32. J. J. Sung, J. Y. Lau, K. L. Goh, and W. K. Leung, "Increasing incidence of colorectal cancer in Asia: implications for screening," The Lancet Oncology, Vol. 6, no. 11, pp. 871-876, 2005.
33. E. Quintero, A. Castells, L. Bujanda et al., "Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening," The New England Journal of Medicine, Vol. 366, no. 8, pp. 697-706, 2012.
34. R. E. Schoen, P. F. Pinsky, J. L. Weissfeld et al., "Colorectal-cancer incidence and mortality with screening flexible sigmoi-doscopy," The New England Journal of Medicine, Vol. 366, no. 25, pp. 2345-2357, 2012.
35. S. B. Baylin, "Mechanisms underlying epigenetically mediated gene silencing in cancer," Seminars in Cancer Biology, Vol. 12, no. 5, pp. 331-337, 2002.
36. P. W. Laird, "The power and the promise of DNA methylation markers," Nature Reviews Cancer, Vol. 3, no. 4, pp. 253-266, 2003.
37. W. M. Grady, A. Rajput, J. D. Lutterbaugh, and S. D. Markowitz, "Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer," Cancer Research, Vol. 61, no. 3, pp. 900-902, 2001.
38. N. Shivapurkar and A. F. Gazdar, "DNA methylation based biomarkers in non-invasive cancer screening," Current Molecular Medicine, Vol. 10, no. 2, pp. 123-132, 2010.
39. N. J. Belshaw, G. O. Elliott, E. A. Williams et al., "Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer," Cancer Epidemiology Biomarkers and Prevention, Vol. 13, no. 9, pp. 1495-1501, 2004.
40. W.-D. Chen, Z. J. Han, J. Skoletsky et al., "Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene," Journal of the National Cancer Institute, Vol. 97, no. 15, pp. 1124-1132, 2005.
41. K. Lenhard, G. T. Bommer, S. Asutay et al., "Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer," Clinical Gastroenterology and Hepatology, Vol. 3, no. 2, pp. 142-149, 2005.
42. W. K. Leung, K.-F. To, E. P. S. Man et al., "Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study," Clinical Chemistry, Vol. 50, no. 11, pp. 2179-2182, 2004.
43. Z. Petko, M. Ghiassi, A. Shuber et al., "Aberrantly methylated CDKN2A, MGMT, and MLH1 incolonpolyps and in fecal DNA from patients with colorectal polyps," Clinical Cancer Research, Vol. 11, no. 3, pp. 1203-1209, 2005.
44. X.-D. Wu, Y.-C. Song, P.-L. Cao et al., "Detection of miR-34a and miR-34b/c in stool sample as potential screening biomarkers for noninvasive diagnosis of colorectal cancer," Medical Oncology, Vol. 31, no. 4, article 894, 2014.
45. H. Zhang, Y.-C. Song, and C.-X. Dang, "Detection of hyperme-thylated spastic paraplegia-20 in stool samples of patients with colorectal cancer," International Journal of Medical Sciences, Vol. 10, no. 3, pp. 230-234, 2013.
46. W. M. Grady and J. M. Carethers, "Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis," Gastroenterology, Vol. 135, no. 4, pp. 1079-1099, 2008.
47. J. G. Herman, J. R. Graff, S. Myöhänen, B. D. Nelkin, and S. B. Baylin, "Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands," Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, no. 18, pp. 9821-9826, 1996.
48. C. Lengauer, "Cancer. An unstable liaison," Science (New York, NY), Vol. 300, no. 5618, pp. 442-443, 2003.
49. S. B. Baylin and J. E. Ohm, "Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction?" Nature Reviews Cancer, Vol. 6, no. 2, pp. 107-116, 2006.
50. P. A. Jones and S. B. Baylin, "The fundamental role of epigenetic events in cancer," Nature Reviews Genetics, Vol. 3, no. 6, pp. 415-428, 2002.
51. R. F. Schwabe and C. Jobin, "The microbiome and cancer," Nature Reviews Cancer, Vol. 13, no. 11, pp. 800-812, 2013.
52. G. E. Lind, S. A. Danielsen, T. Ahlquist et al., "Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas," Molecular Cancer, Vol. 10, article 85, 2011.
53. Q. Guo, Y. Song, H. Zhang, X. Wu, P. Xia, and C. Dang, "Detection of hypermethylated fibrillin-1 in the stool samples of colorectal cancer patients," Medical Oncology, Vol. 30, no. 4, article 695, 2013.
54. J. E. Allison, I. S. Tekawa, L. J. Ransom, and A. L. Adrain, "A comparison of fecal occult-blood tests for colorectal-cancer screening," The New England Journal of Medicine, Vol. 334, no. 3, pp. 155-159, 1996.
55. G. Castiglione, M. Zappa, G. Grazzini et al., "Immunochemical vs guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer," British Journal of Cancer, Vol. 74, no. 1, pp. 141-144, 1996.
56. X. Wang, Y. Y. Kuang, and X. T. Hu, "Advances in epigenetic biomarker research in colorectal cancer," World Journal of Gastroenterology, Vol. 20, no. 15, pp. 4276-4287, 2014.
57. C. Ostwald, M. Linnebacher, V. Weirich, and F. Prall, "Chromo-somally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification," International Journal of Oncology, Vol. 35, no. 2, pp. 321-327, 2009.
58. L. J. W. Bosch, S. Mongera, J. S. T. S. Droste et al., "Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection," Cellular Oncology, Vol. 35, no. 4, pp. 309-315, 2012.